Of course there are ethical transactions that can break the mold. Gilead was an ethical player. For instance, it dared to cure hepatitis C.

That doesn’t change the fact that there are small biotech companies whose market caps are beaten down by unscrupulous players, and then those small biotech companies are bought for cheap.

Your argument that some unscrupulous players would rather buy a company for more because that high purchase cost would eventually enable them to sell their product for more goes in the category of silly.

Not something you have to prove when alleging spoofing.

However, Merck is one of Citadel’s investment arm’s largest holdings.

This may come as a surprise, but BP do better financially if they buy brilliant small companies on the cheap after the small brilliant companies have their market cap beaten to a fricking pulp.

This may also come as a surprise, but Citadel profits from companies that also own BP. Many of those companies want small brilliant company market caps beaten to a fricking pulp.

This may also come as a surprise, but large hedge fund/brokerages/market makers have high incentive to break firewalls and little worry about regulators enforcing disabled firewalls. Wet noodle wrist slaps.

I’ve never seen a shareholder not want an initial offer more than DocLogic. It defies logic. Bare minimum, we stop diluting at half a dollar.

RFI is very common, although, then again, I don’t know of any other company that’s hired two maa editors, and spent months conducting mock inspection preparations.

In December, on announcing maa submission, the company themselves expected an RFI as part of the typical process.

🙄 🙄🙄

Effectively, imo, the motion to dismiss has already been denied. While legally granted, the right to specifically cure by amendment regarding causation, combined with Ms. Posner’s guarantee they are “fully prepared” to provide exactly what the court asks for and anything else, means that the time for settlement possibility that you are talking about starts now, imo. Particularly with the cookie cutter amended pleading eagerly awaited by all kinds of companies within the week.

Not on mine. For years, the app has given me real time, now it exclusively delayed NWBO from real time, all others on watchlist app remain real time.

For the last half hour now, NWBO trade postings have been delayed 15 minutes on CNBC. All other companies are within seconds of real time.

CNBC licking KG’s boots? NWBO no longer real time on CNBC.

Sweden!

It is a bizarre world when money traders believe they are more entitled than the companies they provide liquidity for. It’s as if the “market makers” of this world see their penny skimming billion dollar schemes as more important than cancer research, sattelite innovation, electric transportation developments and artificial intelligence.

They are figuratively and literally too big for their britches.

Thanks for adding the transcript link.

Update: 03/08/24

I know I’m probably wrong, but my guess is that there’s a strong possibility of near term settlement in the MM case.

My reasoning is based upon easily publicly available material — court rulings, newspaper articles, etc.

I’m not going to go into my reasoning, as it’s quite possibly wrong anyway. I’ll just say the magistrate's recommendation is not being clearly spelled out by some in the media, and I don’t think this is by chance.

Still, I would not be surprised to see the case go forward, and my assumptions be found lacking.

We are essentially a week from the 2nd amended complaint filing deadline.

According to his responses here, Nemesis19 was never admitted into the clinical trial. In fact, he states he was only ever offered standard of care. At first, he tried to make it seem he was duped into a trial. It later appears he was only offered standard of care and never offered any trial therapy.

I don’t believe Nemesis19 was a patient, but is a message poster parading around patient records, with or without patient permission.

His language errors are that of a non-native english speaking foreign national, or of someone trying to feign being a non-native English speaking foreign national.

Just my opinion.

Who was the “oncologist” you were referred to after being called by the nurse specialist and being told you have two weeks to live?

Who was your surgeon?

Was your tumor tissue wax paraffined or frozen?

I know, so what’s he going on about? If he wasn’t randomized, the screening process did its job.

Were you randomized into the trial. In other words, were you assigned to start vaccine treatment before you left the “study.”

Yes or no?

Ours, earlier:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021071977

Theirs, later:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021102057

My guess is we in-licensed theirs as a precaution.

I think we filed in July 2020 and Children’s Medical Center Cororation filed in November 2020. We also had priority data ahead of them in 2019.

My guess is we in-licensed their IP in 2023.

(Again, referencing Hyperactive Dendritic Cells) Next Generation.

If granted, patent might go out to 2040.

Hyperactive Dendritic Cells. IMO.

In-licensed, imo. We had/have a parallel patent application for this with a separate institution. I wondered what was going on with that, and now it makes sense.

He found it on page 5 of the 10k. Middle of page.

Remembering Temodar can suppress the immune response, and in particular, incapacitate the t-cell response, I am not surprised that we will soon read the compelling case study below showing DCVax-l impact with immune enhancing diet.

They are talking about 2023 as conditions were then.

Continued.

You’re welcome.

Now ask yourself, why did they say they will continue to monitor timelines.

You are trying to correct something that was correct in the first place. It said “appraisal.”

Continued: Got it? Now read this with a more discerning eye.

National approvals were difficult for MHRA for a couple years after Brexit.

New target dates helped quantify this struggle, and allowed them to start tweaking guidelines to increase efficiency.

Now, because the IRP program is dividing international marketing application reviews away from the national reviews, national reviews are more focused with veteran teams.

Additionally, while funding has increased for the new IRP program and its staff, this effectively allows the national program to remain robust with smaller case review demand, thus speeding reviews, which is why we are suddenly seeing a dramatic shift. Imho.

The NICE title changed from:

(Before) “DCVax-L for treating newly diagnosed glioblastoma”

(Now) “DCVax-L for treating glioblastoma”

to

It is also now designated as a single technology appraisal “STA”

Smart

Senti, you need to clarify your response was not talking about captain obvious.

No, hospital exemption and other compassionate use goes back further than a decade. To get the PIMS in September 2014, they had to provide months/years of data prior. We are well over a decade of established use of this medicine.

“Who cares what you say”? You are an ignorant poster not providing links to your own assertions giving an alternative definition of established medicine in your last sentence.

See:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173967586

See:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173967586

Also: see:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173967586

George Bailey said: